Hectorol Will Drive Genzyme’s Renal Business; “Share Of Voice” To Jump
Executive Summary
Genzyme expects its acquisition of Bone Care International will drive sales of both Hectorol (doxercalciferol) and Renagel (sevelamer) through the strength of joint promotions
You may also be interested in...
Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say
FDA posts non-compliance letters and responses from three sponsors that failed to meet deadlines for submitting reports for trials of four drugs in children; more than 70 firms have had their deadlines extended.
Cytochroma Seeks To Bring Advance Over Hectorol, Zemplar To Market For CKD
Phase II candidate CTA018 is intended as safer alternative to existing hormone replacement therapies for vitamin D insufficiency.
Myozyme Extensive Phase IV Program Includes Trial In Late-Onset Pompe
Genzyme's Phase IV commitments for the Pompe disease therapy Myozyme (alglucosidase alfa) include randomized trials in late-onset Pompe disease patients